Zophar Plus 3mg/2mg Tablet is a combination medication containing Risperidone 3mg and Trihexyphenidyl 2mg, indicated for the management of schizophrenia and extrapyramidal symptoms associated with antipsychotic therapy. Risperidone, an atypical antipsychotic, exerts its therapeutic effect by antagonizing dopamine D2 and serotonin 5-HT2A receptors, thereby helping to alleviate psychotic symptoms such as hallucinations, delusions, and disorganized thinking. Trihexyphenidyl, an anticholinergic agent, is included to counteract extrapyramidal side effects like dystonia, parkinsonism, and akathisia that may arise from dopamine receptor blockade. This combination enhances patient compliance by addressing both psychotic symptoms and movement disorders concurrently. Zophar Plus is administered orally, with dosage tailored to individual patient needs based on clinical response and tolerability. Caution is advised in patients with a history of cardiovascular disease, glaucoma, or urinary retention. Common adverse effects include sedation, dry mouth, dizziness, and gastrointestinal disturbances. Regular monitoring of mental status, extrapyramidal symptoms, and metabolic parameters is recommended during treatment. This medication should be used under strict medical supervision, considering potential drug interactions and contraindications to optimize therapeutic outcomes and minimize adverse effects.